Search Results

There are 6730 results for: content related to: Acute generalized exanthematous pustulosis induced by gliclazide: a case report

  1. Acute generalized exanthematous pustulosis: atypical presentations and outcomes

    Journal of the European Academy of Dermatology and Venereology

    Volume 29, Issue 2, February 2015, Pages: 209–214, T.C. Kostopoulos, S.M. Krishna, N.K. Brinster and A.G. Ortega-Loayza

    Version of Record online : 8 SEP 2014, DOI: 10.1111/jdv.12721

  2. Double-blind, randomized, multicentre study of the efficacy and safety of gliclazide-modified release in the treatment of Chinese type 2 diabetic patients

    Diabetes, Obesity and Metabolism

    Volume 8, Issue 2, March 2006, Pages: 184–191, C.-H. Lu, C.-C. Chang, L.-M. Chuang, C. Y. Wang, Y. D. Jiang and H. P. Wu

    Version of Record online : 28 OCT 2005, DOI: 10.1111/j.1463-1326.2005.00501.x

  3. Severe flucloxacillin-induced acute generalized exanthematous pustulosis (AGEP), with toxic epidermal necrolysis (TEN)-like features: does overlap between AGEP and TEN exist? Clinical report and review of the literature

    British Journal of Dermatology

    Volume 171, Issue 6, December 2014, Pages: 1539–1545, S. van Hattem, G.I. Beerthuizen and S.H. Kardaun

    Version of Record online : 9 NOV 2014, DOI: 10.1111/bjd.13152

  4. Nateglinide or gliclazide in combination with metformin for treatment of patients with type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone: 1-year trial results

    Diabetes, Obesity and Metabolism

    Volume 9, Issue 4, July 2007, Pages: 506–511, S. Ristic, C. Collober-Maugeais, F. Cressier, P. Tang and E. Pecher

    Version of Record online : 7 AUG 2006, DOI: 10.1111/j.1463-1326.2006.00632.x

  5. The histopathological spectrum of acute generalized exanthematous pustulosis (AGEP) and its differentiation from generalized pustular psoriasis

    Journal of Cutaneous Pathology

    Volume 37, Issue 12, December 2010, Pages: 1220–1229, Sylvia H. Kardaun, Hilde Kuiper, Vaclav Fidler and Marcel F. Jonkman

    Version of Record online : 24 AUG 2010, DOI: 10.1111/j.1600-0560.2010.01612.x

  6. Design and development of gliclazide-loaded chitosan microparticles for oral sustained drug delivery: in-vitro/in-vivo evaluation

    Journal of Pharmacy and Pharmacology

    Volume 63, Issue 2, February 2011, Pages: 169–178, Nahla S. Barakat and Alanood S. Almurshedi

    Version of Record online : 14 JAN 2011, DOI: 10.1111/j.2042-7158.2010.01214.x

  7. Acute generalized exanthematous pustulosis: clinical characteristics, etiologic associations, treatments, and outcomes in a series of 28 patients at Mayo Clinic, 1996–2013

    International Journal of Dermatology

    Volume 56, Issue 4, April 2017, Pages: 405–414, Dema T. Alniemi, David A. Wetter, Alina G. Bridges, Rokea A. el-Azhary, Mark D. P. Davis, Michael J. Camilleri and Marian T. McEvoy

    Version of Record online : 13 JAN 2017, DOI: 10.1111/ijd.13434

  8. You have free access to this content
    Pharmacokinetics and pharmacodynamics of gliclazide in Caucasians and Australian Aborigines with type 2 diabetes

    British Journal of Clinical Pharmacology

    Volume 49, Issue 3, March 2000, Pages: 223–230, Timothy M. E. Davis,, Frank Daly,, John P. Walsh,, Kenneth F. Ilett,, John P. Beilby,, Leon J. Dusci and P. Hugh R. Barrett

    Version of Record online : 24 DEC 2001, DOI: 10.1046/j.1365-2125.2000.00162.x

  9. Systemic involvement of acute generalized exanthematous pustulosis: a retrospective study on 58 patients

    British Journal of Dermatology

    Volume 169, Issue 6, December 2013, Pages: 1223–1232, C. Hotz, L. Valeyrie-Allanore, C. Haddad, S. Bouvresse, N. Ortonne, T.A. Duong, S. Ingen-Housz-Oro, J.C. Roujeau, P. Wolkenstein and O. Chosidow

    Version of Record online : 2 DEC 2013, DOI: 10.1111/bjd.12502

  10. The spectrum of histopathological features in acute generalized exanthematous pustulosis: a study of 102 cases

    British Journal of Dermatology

    Volume 163, Issue 6, December 2010, Pages: 1245–1252, S. Halevy, S.H. Kardaun, B. Davidovici, J. Wechsler and for the EuroSCAR and RegiSCAR study group

    Version of Record online : 2 AUG 2010, DOI: 10.1111/j.1365-2133.2010.09967.x

  11. Risk factors for acute generalized exanthematous pustulosis (AGEP)—results of a multinational case–control study (EuroSCAR)

    British Journal of Dermatology

    Volume 157, Issue 5, November 2007, Pages: 989–996, A. Sidoroff, A. Dunant, C. Viboud, S. Halevy, J.N. Bouwes Bavinck, L. Naldi, M. Mockenhaupt, J-P. Fagot and J-C. Roujeau

    Version of Record online : 13 SEP 2007, DOI: 10.1111/j.1365-2133.2007.08156.x

  12. The Effect of Sulphonylurea Therapy on Skeletal Muscle Glycogen Synthase Activity and Insulin Secretion in Newly Presenting Type 2 (Non-insulin-dependent) Diabetic Patients

    Diabetic Medicine

    Volume 8, Issue 3, April 1991, Pages: 243–253, Dr. A. B. Johnson, M. Argyraki, J. C. Thow, I. R. Jones, D. Broughton, M. Miller and R. Taylor

    Version of Record online : 30 JUL 2009, DOI: 10.1111/j.1464-5491.1991.tb01580.x

  13. Using resonance light scattering and UV/vis absorption spectroscopy to study the interaction between gliclazide and bovine serum albumin

    Luminescence

    Volume 31, Issue 5, August 2016, Pages: 1109–1114, Qiu-Ju Zhang, Bao-Sheng Liu, Gai-Xia Li and Rong Han

    Version of Record online : 14 DEC 2015, DOI: 10.1002/bio.3079

  14. You have free access to this content
    Randomized trial comparing the effects of gliclazide, liraglutide, and metformin on diabetes with non-alcoholic fatty liver disease

    Journal of Diabetes

    Volume 9, Issue 8, August 2017, Pages: 800–809, Wenhuan Feng, Caixia Gao, Yan Bi, Min Wu, Ping Li, Shanmei Shen, Wei Chen, Tingting Yin and Dalong Zhu

    Version of Record online : 29 MAY 2017, DOI: 10.1111/1753-0407.12555

  15. A long-term comparison of pioglitazone and gliclazide in patients with Type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial

    Diabetic Medicine

    Volume 22, Issue 4, April 2005, Pages: 399–405, B. H. Charbonnel, D. R. Matthews, G. Schernthaner, M. Hanefeld, P. Brunetti and on behalf of the QUARTET Study Group

    Version of Record online : 27 OCT 2004, DOI: 10.1111/j.1464-5491.2004.01426.x

  16. You have free access to this content
    Severe drug-induced skin reactions: clinical pattern, diagnostics and therapy

    JDDG: Journal der Deutschen Dermatologischen Gesellschaft

    Volume 7, Issue 2, February 2009, Pages: 142–162, Maja Mockenhaupt

    Version of Record online : 26 JAN 2009, DOI: 10.1111/j.1610-0387.2008.06878.x

  17. Pharmacokinetics of gliclazide in healthy and diabetic subjects

    Journal of Pharmaceutical Sciences

    Volume 73, Issue 12, December 1984, Pages: 1684–1687, Kunio Kobayashi, Masako Kimura, Takafumi Sakoguchi, Ayumi Hase, Akira Matsuoka and Shigeo Kaneko

    Version of Record online : 18 SEP 2006, DOI: 10.1002/jps.2600731204

  18. Gliclazide modified release: results of a 2-year study in patients with type 2 diabetes

    Diabetes, Obesity and Metabolism

    Volume 6, Issue 6, November 2004, Pages: 414–421, P. Drouin, E. Standl and for the Diamicron MR Study Group

    Version of Record online : 8 OCT 2004, DOI: 10.1111/j.1462-8902.2004.00404.x

  19. Risk of acute coronary events associated with glyburide compared with gliclazide use in patients with type 2 diabetes: a nested case–control study

    Diabetes, Obesity and Metabolism

    Volume 16, Issue 1, January 2014, Pages: 22–29, A. S. Abdelmoneim, D. T. Eurich, J. M. Gamble, J. A. Johnson, J. M. Seubert, W. Qiu and S. H. Simpson

    Version of Record online : 19 JUL 2013, DOI: 10.1111/dom.12173

  20. Effect of rifampin on the pharmacokinetics and pharmacodynamics of gliclazide

    Clinical Pharmacology & Therapeutics

    Volume 74, Issue 4, October 2003, Pages: 334–340, Ji-Young Park, Kyoung-Ah Kim, Pil-Whan Park, Chan-Woong Park and Jae-Gook Shin

    Version of Record online : 11 NOV 2003, DOI: 10.1016/S0009-9236(03)00221-2